Primer: Shionogi & Co (4507 JP) - Aug 2026
Shionogi is forecasting robust top-line growth of 40% for FY27, primarily driven by its strategic acquisitions, expansion in the U.S. market,...
109 Views
Curator's Cut: Soft Commodities' Hard Truths, Pricing China's Hi-Tech & Sumitomo Pharma's Placement
​This Curator's Cut highlights supply-side risks in agri-commodities, China hard-tech IPOs, and Sumitomo Pharma's share placement. Share your topic...
345 Views
APAC Healthcare Weekly (Sept 20) –Sino Bio, Impact Therapeutics, Takeda, Daiichi Sankyo, SK Biopharm
NMPA accepted Sino Bio’s NDA for bispecific ADC drug candidate. FDA granted priority review to Takeda’s zasocitinib for moderate-to-severe plaque...
92 Views
Shionogi & Co (4507 JP): FY26 Result Falls Short of Expectation; Mixed Guidance for FY27
​Shionogi announces FY26 results, with revenue meeting but operating profit missing guidance due to higher expenses. The company expects 32%...
96 Views
Primer: Shionogi & (4507 JT) - May 2026
Shionogi's growth is underpinned by its successful HIV franchise, which generates substantial royalty income through its partnership with ViiV...
113 Views